LFA
NBIX icon

Legacy Financial Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Legacy Financial Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$250K Buy
1,896
+293
+18% +$38.9K 0.03% 355
2025
Q4 		$227K Buy
+1,603
New +$232K 0.03% 362
2018
Q4 		– Sell
-540
Closed -$66K – 1030
2018
Q3 		$66K Buy
+540
New +$61.3K 0.02% 216

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Legacy Financial Advisors's NBIX Position: Q1 2026 in Review

Legacy Financial Advisors increased its Neurocrine Biosciences (NBIX) stake by 18% in Q1 2026, buying an estimated $38.9K and bringing the position to 1,896 shares worth $250K. The position accounts for 0.03% of the portfolio, ranked #355.

Legacy Financial Advisors first reported a position in NBIX in Q3 2018 and has held it in 3 quarters since. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Legacy Financial Advisors held 1,896 shares of Neurocrine Biosciences worth $250K as of Q1 2026.
  • Legacy Financial Advisors bought 293 Neurocrine Biosciences shares in Q1 2026, an estimated $38.9K.
  • Neurocrine Biosciences made up 0.03% of Legacy Financial Advisors's portfolio in Q1 2026, its #355 holding.
  • Legacy Financial Advisors first reported a position in Neurocrine Biosciences in Q3 2018 and has held it in 3 quarters since.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Legacy Financial Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.